左卡尼汀对终末期肾病血液透析患者心功能及CTGF、NT-ProBNP的影响

doi:10.3969/j.issn.10073205.2017.09.005

摘要/Abstract

摘要： ［摘要］〓
〖HTH〗目的〖HTSS〗〖KG*2〗观察左卡尼汀对终末期肾病血液透析患者心功能及结缔组织生长因子(connective tissue growth factor,CTGF)、N末端脑钠肽原（Nterminal probrain natriuretic peptide, NTProBNP）的影响，探讨左卡尼汀对患者的临床应用价值。
〖HTH〗方法〖HTSS〗〖KG*2〗选取血液净化中心收治的终末期肾病患者124例，采用随机数字表法将其分成对照组和观察组各62例。对照组采取血液透析治疗，观察组在对照组治疗的基础上再采取左卡尼汀化疗，比较2组心功能、CTGF及NTProBNP水平。
〖HTH〗结果〖HTSS〗〖KG*2〗与治疗前相比，2组红细胞比容（hematocrit，Hct）、血红蛋白（haemoglobin，Hb）均获得改善，差异有统计学意义（P＜005）。与对照组相比，观察组治疗后Hct、Hb均明显改善，差异有统计学意义（P＜005）。与治疗前相比，2组
左心室射血分数（left ventricular ejection fraction，LVEF）、每分排出量（cardiac output,CO）、心脏指数（cardiac index，CI）、每搏排出量（stroke volume,SV）均明显改善，差异有统计学意义（P＜005）。与对照组相比，观察组治疗后LVEF、CO、CI、SV、心肌收缩力指数（heather index，HI）和左心室质量指数（left ventricular mass index,LVMI）均明显改善，差异有统计学意义（P＜005）。与治疗前相比，2组CTGF、NTProBNP均明显降低，差异有统计学意义（P＜005）。与对照组相比，观察组治疗后CTGF、NTProBNP水平均明显更低，差异有统计学意义（P＜005）。
〖HTH〗结论〖HTSS〗〖KG*2〗左卡尼汀可改善终末期肾病血液透析患者贫血、心功能，并降低CTGF、NTProBNP水平，促进受损心肌细胞修复，恢复患者的心肌收缩功能，可为临床治疗提供参考。

关键词: 肾病, 左卡尼汀, 心功能, 结缔组织生长因子

Abstract: ［Abstract］ Objective〖HTSS〗〓To analyze the effect of Lcarnitine on heart function, blood connective tissue, growth factor (CTGF) and Nterminal probrain natriuretic peptide (NTProBNP) of patients with end stage renal disease and dialysis.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 124 cases of maintenance hemodialysis patients were selected. All patients were divided into control group and observation group with 62 cases in each group. The patients in the control group were treated with hemodialysis. The patients in the observation group were treated with Lcarnitine for chemotherapy. The cardiac function, CTGF and NTProBNP levels in the two groups were analyzed.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓Compared with pretreatment group, the hematocrit(Hct) and haemoglobin(Hb) of the two groups were improved, the difference was statistically significant（P＜005）. Compared with the control group, the Hct and Hb of the observation group were improved significantly after treatment, the difference was statistically significant （P＜005）. Compared with pretreatment group, left ventricular ejection fraction(LVEF), cardiac output(CO), cardiac index(CI) and stroke volume(SV) of control group and observation group were significantly improved, and the difference was statistically significant (P＜005). Compared with the control group, the LVEF, CO, CI, SV, heather index（HI） and left ventricular mass index(LVMI) of the observation group were significantly improved after treatment, the difference was statistically significant (P＜005). Compared with the control group, the levels of CTGF and NTProBNP in the observation group and the control group were significantly lower than those in the control group (P＜005), and the difference was statistically significant. The levels of CTGF and NTProBNP were significantly lower in the treatment group (P＜005), and the difference was statistically significant.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓 Lcarnitine can improve the anemia and cardiac function of patients with endstage renal disease and hemodialysis, and reduce the levels of CTGF and NTProBNP, promote the repair of damaged cardiac muscle cells and restoring myocardial contractility of patients. It can provide reference for clinical treatment.

Key words: nephrosis； Lcarnitine, cardiac function, connective tissue growth factor

孙建洁，陈〓超，麦李明，田〓路，姚素花，石〓峰. 左卡尼汀对终末期肾病血液透析患者心功能及CTGF、NT-ProBNP的影响[J]. 河北医科大学学报, doi: 10.3969/j.issn.10073205.2017.09.005.

SUN Jianjie， CHEN Chao， MAI Liming， TIAN Lu， YAO Suhua， SHI Feng. Effect of Lcarnitine on heart function, blood CTGF and NT-ProBNP of patients with end stage renal disease and dialysis[J]. Journal of Hebei Medical University, doi: 10.3969/j.issn.10073205.2017.09.005.

[1]	唐乐丽, 叶桂花. 2022年《免疫介导肾病患者接种COVID-19疫苗前景：ERA-IWG和EUVAS的共识声明》解读 [J]. 河北医科大学学报, 2023, 44(6): 621-628.
[2]	邢玉微, 孙泽楠, 柴雪姣, 位庚. 外周血miR-92b-5p与miR-148b-3p在2型糖尿病进展至糖尿病肾病中的表达及交互作用 [J]. 河北医科大学学报, 2023, 44(6): 654-659.
[3]	张楠, 莫小兰, 魏雪芹, 李三妮, 东蕾, 赵宜乐. 原发性肾病综合征患儿合并肺炎的病原学特点及抗感染药物分析 [J]. 河北医科大学学报, 2023, 44(6): 729-732.
[4]	谷梁, 马小溪. 甲状腺激素水平与糖尿病肾病患者高尿酸血症发生的相关性 [J]. 河北医科大学学报, 2023, 44(4): 407-411.
[5]	冯玉平, 吴得安, 何振东, 马春芳, 庞增林, 张乐乐. 不同创伤严重程度的多发伤患者血清心肌酶谱指标水平变化及对MODS中心功能障碍的预测价值 [J]. 河北医科大学学报, 2023, 44(4): 417-422,449.
[6]	白金录, 刘照龙, 杨丽娜, 卞海艳, 李侠. 血清SERPINA1、CTGF、T-AOC在子宫肌瘤患者中的表达水平及临床意义 [J]. 河北医科大学学报, 2023, 44(4): 434-438.
[7]	李文亚, 高颖, 汤颖, 邓雁北. 达格列净联合厄贝沙坦对糖尿病肾病患者尿ACR、肾小球滤过率、 CysC水平的影响 [J]. 河北医科大学学报, 2022, 43(8): 904-908.
[8]	姚鹏云, 龚亚萍, 高佳琪. CysC、IL-2、C3在慢性肾小球肾病患者中的水平及相关性研究 [J]. 河北医科大学学报, 2022, 43(6): 641-645,650.
[9]	姜姣姣, 邵云侠, 董雄军, 汪正翔, 朱亚宁. IRF1、IRF8水平与2型糖尿病肾病患者颈动脉粥样硬化的关系[J]. 河北医科大学学报, 2021, 42(9): 1027-1031.
[10]	王菡, 陈卫东, 丁志珍, 陈燕. 慢性肾脏病患者血清骨硬化蛋白与矿物质和骨异常的相关性研究[J]. 河北医科大学学报, 2021, 42(6): 671-675,694.
[11]	陈亚坤, 任瑞华, 王晓荣, 张春霞, 傅淑霞. 环孢素和他克莫司治疗特发性膜性肾病伴肾病综合征患者的效果及安全性[J]. 河北医科大学学报, 2021, 42(5): 525-530.
[12]	罗长志, 侯培勇, 苏奕明, 许太福. 血管腔内治疗致造影剂肾病的相关危险因素分析[J]. 河北医科大学学报, 2021, 42(5): 551-554,596.
[13]	陈静, 王茜, 王凯, 李文建, 李易明. 姜黄素通过miR-146a抑制NF-κB信号通路保护大鼠糖尿病肾病的机制研究[J]. 河北医科大学学报, 2021, 42(2): 134-139.
[14]	王欣, 雷琳, 卢彩平, 刘晨曦, 任巧华, 吴韬. 利拉鲁肽治疗超重、肥胖2型糖尿病并肾脏疾病的临床观察[J]. 河北医科大学学报, 2021, 42(12): 1401-1405.
[15]	李晓东, 李欣悦, 韩永斌, 李宝新. 糖尿病肾病高尿酸血症的危险因素研究[J]. 河北医科大学学报, 2021, 42(12): 1406-1410.

左卡尼汀对终末期肾病血液透析患者心功能及CTGF、NT-ProBNP的影响

Effect of Lcarnitine on heart function, blood CTGF and NT-ProBNP of patients with end stage renal disease and dialysis

HTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价